Sector News

Medivir plans split into two companies

August 31, 2016
Life sciences

Medivir said today it will split by year’s end into two companies—one focused on developing its drug portfolio, the other focused on commercial operations.

“The objective of the separation is to visualize the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio,” Medivir said in a statement.

The commercial company will oversee the company’s 15 marketed drugs. One is the hepatitis C treatment Olysio® (simeprevir), an NS3/4A protease inhibitor jointly developed by Medivir and Johnson & Johnson’s Janssen R&D Ireland.

Another is Adasuve® (loxapine), an inhaled medicine for acute treatment of agitation associated with schizophrenia or bipolar I disorder. Medivir launched Adasuve in Sweden, Norway, Finland, and Denmark in 2013 under license from Ferrer—which earlier this year acquired Adasuve developer Alexza Pharmaceuticals.

Also to be marketed by the commercial company are the 13 drugs that form Medivir’s Nordic Brands Portfolio, which the company obtained through the acquisition of BioPhausia in 2011. The 13 have indications related to central nervous system (CNS), cardiovascular system, gout, musculoskeletal system, pain, respiratory system, stomach/intestine, and zinc deficiency.

The commercial company will have a separate public listing on the First North Premium exchange.

The R&D-focused company will develop Medivir’s pipeline, whose sole clinical candidate is MIV-711, a cathepsin K inhibitor indicated for the treatment of osteoarthritis. MIV-711 is the subject of a Phase IIa trial assessing the candidate in patients with moderate knee osteoarthritis. Data is expected to be available in the third quarter of 2017.

The company’s preclinical candidates include a nucleotide DNA polymerase inhibitor indicated for hepatocellular carcinoma and a respiratory syncytial virus (RSV) fusion protein inhibitor indicated for RSV infection. Discovery-phase candidates include an human immunodeficiency virus (HIV) protease inhibitor being developed in partnership with Janssen.

Earlier this month, Medivir sold rights to another preclinical candidate—MIV-802, a nucleotide-based polymerase inhibitor indicated for hepatitis C virus—to Trek Pharmaceuticals for an undisclosed price. Those rights covered most of the world, except China, Taiwan, Hong Kong, and Macau.

Medivir said it will provide additional details on the corporate split at a future capital markets day.

Source: GEN

comments closed

Related News

June 16, 2024

Bayer’s biotech head Jens Vogel says good-bye after 4 years

Life sciences

While Vogel didn’t cite any broader organizational changes as the reason behind his resignation, his departure comes amid a heavy-handed restructuring at the German pharma. Back in January, Bayer unveiled plans that have ultimately led to the elimination of more than 1,500 roles in the first three months of 2024.

June 16, 2024

Ventilator maker Vyaire Medical files for bankruptcy

Life sciences

The global ventilation and respiratory device manufacturer—originally spun out as a joint venture between BD and Apax Partners in 2016—said its decision followed “below-plan performance in the first half of the financial year, which frustrated efforts to refinance company debt,” and that Vyaire will remain open for business in the interim.

June 16, 2024

Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity

Life sciences

Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration, and it’s not exactly a surprise: The New York Big Pharma giant will work with the venture creation firm’s ProFound Therapeutics to develop new obesity drugs.

How can we help you?

We're easy to reach